SCCM Resource Library-What New Therapies, Such as CAR T Cell Therapy, Are the Oncologists Bringing to the ICU?

Video Transcription

Video Summary

CAR-T cell therapy is a promising treatment that modifies a patient's T cells to target and kill cancer cells. However, it comes with toxicities, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). CRS is caused by the release of cytokines from activated T cells and can cause fever, hypotension, and organ dysfunction. The main treatment for CRS is tocilizumab, an IL-6 receptor antagonist. ICANS is characterized by neurologic symptoms and requires early imaging, seizure prophylaxis, and frequent neurologic examinations. Collaboration between oncology, neurology, and intensive care teams is crucial in managing these toxicities. Further research is needed in areas like infection prevention, biomarker use, and toxicity prediction. Close monitoring and a multidisciplinary approach are essential in managing toxicities associated with CAR-T cell therapy.

Asset Subtitle

Immunology, 2020

Asset Caption

The Society of Critical Care Medicine's Critical Care Congress features internationally renowned faculty and content sessions highlighting the most up-to-date, evidence-based developments in critical care medicine. This is a presentation from the 2020 Critical Care Congress held February 16-19, 2020, in Orlando, Florida, USA.

Learning Objectives

Review common and newer biologic therapies pertinent to the ICU patient, indications, and complications
Identify common life-threatening complications of cellular therapy and immunotherapy
Compare strategies for reversing/mitigating complications of cellular and immunotherapy while still maintaining the underlying benefit of the therapy

What's That mAb?

Stephen M. Pastores

ICU Complications of Immune Checkpoint Inhibitors

Joseph L. Nates

Immune Effector Cell Therapy and Clinical Presentation of Common Toxicities

Colleen McEvoy

Treatment of Toxicities of Immune Effector Cell Therapy

Anne Rain T. Brown

Uncommon Toxicities and Other Considerations of Immune Effector Cell Therapy in the ICU

Cristina Gutierrez

Meta Tag

Content Type Presentation

Knowledge Area Immunology

Knowledge Level Advanced

Membership Level Select

Membership Level Professional

Membership Level Associate

Tag Oncology

Tag Genetics

Year 2020

Keywords

CAR-T cell therapy

T cells

cancer cells

toxicities

cytokine release syndrome

CRS

immune effector cell-associated neurotoxicity syndrome

ICANS

tocilizumab

IL-6 receptor antagonist

neurologic symptoms

imaging

seizure prophylaxis

oncology

neurology

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.